Page last updated: 2024-08-24

triazoles and xl765

triazoles has been researched along with xl765 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blackwell, K; Burris, H; Campana, F; Gao, L; Gomez, P; Isakoff, S; Jiang, J; Lynn Henry, N; Macé, S; Tolaney, SM	1

Trials

1 trial(s) available for triazoles and xl765

Article	Year
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. Breast cancer research and treatment, 2015, Volume: 154, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Sulfonamides; Treatment Outcome; Triazoles	2015

Article

Year

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

Breast cancer research and treatment, 2015, Volume: 154, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Sulfonamides; Treatment Outcome; Triazoles

2015